Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPAACT: Adjuvant Pembrolizumab After IMRT in Anaplastic Thyroid Cancer
NCT05059470Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2022
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in anaplastic thyroid carcinoma (ATC), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2022; status: terminated.
02
Drugs
03
Conditions
anaplastic thyroid carcinoma (ATC)
Beyond the preview
Go deeper on NCT05059470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05059470.